Over the past 10 years there has been improvement in the number of recall events attributed to particle contamination of injectable drugs, yet manufacturers need to work harder to improve the quality of these products as the number of injectable recalls overall is still “significant,” a US FDA official says.
To address this problem, the agency is developing a guidance on visual testing programs to improve the quality of sterile...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?